Robot,
I think you're right, next year I believe we'll have greater success than in the recent past, I believe we'll reach a share price in the $5 to $10 range, but in December of next year investors will be saying, Wait until 2025.
Frankly as long as NWBO remains independent, I believe that each succeeding year can be dramatically greater than the past one as long as it's clear that our vaccines work in cancer. The more cancer they're proven to work in, the bigger the company will grow. The more countries that approve our vaccine for use, the bigger the company will grow.
Certainly it's clear that by itself, our vaccine isn't curative, at least not for most patients. The point is, the vaccine leads to incremental change. In some cases, that increment might be small when used with the SOC itself, but as we're finding in GBM, add others and the incremental increase is ten fold over the SOC itself, or over three fold when our vaccine is added to the SOC. GBM is certainly one of the deadliest, I don't know if pancreatic is as bad, or not, but even a small improvement there would be considered huge. On the other hand, if over 90% are already being cured from a given type of cancer, it's hard to say if the regulators will recommend it if it achieves a small incremental improvement there. The potential is huge, even if it's not every solid cancer, but give it time to learn how many it will be.
Gary
AI
Market Data 
Markets 
